Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong

被引：0
|
作者：
Loong, H. [1 ]
Huang, M. [2 ]
Wong, C. [3 ]
Leung, L. [1 ]
Burke, T. [4 ]
Chandwani, S. [4 ]
Law, A. [5 ]
Tan, S. C. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Merck & Co Inc, Ctr Observat & Real World Evidence, N Wales, PA USA
[3] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[4] Merck & Co Inc, Ctr Observat & Real World Evidence, Rahway, NJ 07065 USA
[5] Merck Sharp & Dohme Ltd, Hong Kong, Peoples R China
[6] Merck Sharp & Dohme Asia Pacific, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
cost effectiveness; BTS in Hong Kong; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-050
引用
收藏
页码：S1912 / S1912
页数：1
相关论文
共 50 条
  • [21] New lenvatinib and pembrolizumab combination for metastatic renal cell carcinoma in 1st line drug treatment: comparative effectiveness and safety
    Alekseev, B. Ya
    Shevchuk, I. M.
    ONKOUROLOGIYA, 2022, 18 (03): : 51 - 59
  • [22] Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 140 - 150
  • [23] COST-EFFECTIVENESS OF PEMBROLIZUMAB VS. DO CETAXEL FOR TREATMENT OF PREVIOUSLY TREATED PD-L1 POSITIVE ADVANCED NSCLC PATIENTS
    Huang, M.
    Lou, Y.
    Pellissier, J.
    Burke, T.
    Liu, F. X.
    Xu, R.
    Velcheti, V.
    VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
  • [24] COST EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus FOLFOX AS 1ST LINE OF TREATMENT OF MCRC RAS-WT
    Alva, M. E.
    Vargas, J.
    VALUE IN HEALTH, 2015, 18 (03) : A205 - A205
  • [25] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF PD-L1 POSITIVE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Nedzesky, J.
    Veenstra, D.
    VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
  • [26] THE COST-EFFECTIVENESS OF FISSURE SEALANTS OF 1ST PERMANENT MOLARS WHICH ALSO RECEIVE PERIODICAL TREATMENT WITH FLUORIDE VARNISH
    PETTERSON, E
    PETTERSSON, M
    OLOFSSON, IL
    OGEMAN, B
    SWEDISH DENTAL JOURNAL, 1982, 6 (06) : 259 - 259
  • [27] How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost
    Frueh, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S36 - S36
  • [28] Cost-effectiveness of letrozole vs tamoxifen as 1st line hormonal therapy for postmenopausal women with advanced breast cancer:: the US perspective.
    Delea, T
    Smith, R
    Karnon, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S136 - S136
  • [29] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [30] COST-EFFECTIVENESS ANA LYSES OF NATALIZUMAB FOR 1ST LINE VERSUS INTERFERON BETA-1A 44 MCG IN THE TREATMENT OF HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS IN BRAZIL
    Nishikawa, A. M.
    Paladini, L.
    Liamas, A. L.
    Bueno, C. C.
    Clark, O. A. C.
    VALUE IN HEALTH, 2013, 16 (07) : A721 - A722
12345